Feasibility and outcome of genomics-guided treatment selecti...

🤖 Plain-English Summary

Precision cancer medicine (PCM) is key to advancing cancer treatment beyond the standard of care. Genomics-guided treatment selection in advanced cancer is feasible and safe.

🔑 Key Findings

We performed an explorative clinical trial, MEGALiT, to investigate the feasibility, safety, and clinical benefit of genomics-based PCM in advanced cancer.
MEGALiT recruited adult patients with advanced solid tumors refractory to standard treatment.
Tumor DNA from newly acquired biopsies or ctDNA were analyzed for alterations targetable with the PD-L1 inhibitor atezolizumab, the MEK inhibitor cobimetinib, the mTOR inhibitor everolimus, or the PARP-inhibitor niraparib.

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via PubMed.

View on DOI ↗

📜 Copyright Notice: This page shows only metadata (title, authors, journal, date) and an original AI-generated summary. No abstract or full article text is copied. The original research is the intellectual property of its authors and publisher. ScienceTrace does not reproduce copyrighted content.

← More Medicine & Biology All Research Articles

📋 Article Details

Category	🧬 Medicine & Biology
Published	Jun 04, 2025
Journal	Acta oncologica (Stockholm, Sweden)
Authors	Ny Lars, Fagman Henrik, Botling Johan, Mantovaara Loviisa, Asplund Peter
DOI	10.2340/1651-226X.2025.43366
Source	PubMed

🗂️ Research Categories

🤖 Artificial Intelligence 🧬 Medicine & Biology ⚛️ Physics & Space Science ⚙️ Engineering & Technology ∑ Mathematics

Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial.

🤖 Plain-English Summary

🔑 Key Findings

💡 Why This Matters

📋 Article Details

🗂️ Research Categories

🔗 Related Resources

More 🧬 Medicine & Biology Research